ImmunoCellular Therapeutics To Participate In Webcast Discussion Of Immunotherapy And Brain Cancer On September 23rd

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, and John Yu, MD, Founder and Chief Scientific Officer of ImmunoCellular, will participate in a webcast, titled “Glioblastoma – Brain Cancer: The Next Generation of Therapies,” being sponsored by ProActive Capital Group on Monday, September 23, 2013 at 12 noon ET. The webcast will feature two medical experts in the field of glioblastoma multiforme (GBM) in a moderated discussion of immunological approaches for the treatment of brain cancer:
  • Andrew T. Parsa, MD, PhD, Michael J. Marchese Professor and Chair, Department of Neurological Surgery at Northwestern University School of Medicine;
  • John A. Boockvar, MD, Professor of Neurological Surgery and Co-director of the Brain and Spinal Tumor Program at the Weill Cornell Brain and Spine Center.

The discussion will be moderated by the biotechnology team at Maxim Group, led by Jason Kolbert.

To access the live audio webcast of the discussion, please log on through a link located in the Investors section of ImmunoCellular's website at, under the Events & Presentations tab. Please use passcode 40290515. A replay of the webcast will be available one hour after the conclusion of the live event.

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit

Copyright Business Wire 2010

If you liked this article you might like

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'

5 Stocks Poised for Breakouts

4 Stocks Under $10 to Trade for Breakouts